The record
The industry's own historical screening method, CTFA J4-1, screened talc for amphibole by X-ray diffraction with a nominal amphibole detection limit of 0.5 percent by weight — a threshold under which, FDA states, asbestos 'potentially representing billions of asbestos fibers per gram of talc' would go undetected. FDA also found J4-1 had no utility for detecting chrysotile.
Claim scope
THIS IS THE CRUX OF THE PAGE. A federal agency, in the Federal Register, quantifies the blind spot in the industry method: 0.5 percent by weight, below which the answer is 'not detected' regardless of how many fibers are present. FDA additionally states: 'On review of the protocol, we did not find it to have any utility to test for chrysotile or detect chrysotile with adequate sensitivity,' and concludes 'reliance on XRD, absent any additional microscopic analysis, can lead to false-negative results for talc containing chrysotile asbestos at any level or amphibole asbestos at levels below 0.5 percent.'
What this source does not establish
Does NOT establish that any particular company's historical 'no asbestos detected' result was false — only that the method could not have detected asbestos below that threshold. The distinction matters: this supports 'the test could not see it,' not 'the test saw it and it was hidden.' The 'billions of fibers per gram' figure is FDA's characterization of what 0.5% by weight can represent, not a measurement of any product.
Limitations
J4-1 dates to 1976 (CTFA, 'Asbestiform Amphibole Minerals in Cosmetic Talc'). FDA's critique is of the method's sensitivity, offered in 2024 as justification for requiring TEM.
Source
Federal Register — 89 FR 105490 (Dec. 27, 2024), FR Doc. 2024-30544, discussion of CTFA Method J4-1 (Refs. 34, 37)